NCT05854992Completed
Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women
Source: ClinicalTrials.gov · Last updated 2 Dec 2024
Brief summary (registry, in English)
Researchers are evaluating the safety of triptan treatment of migraine in individuals with elevated cardiovascular risk and in pregnant women.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 68419 (actual)
- First submitted
- 3 May 2023
- Start date
- 5 Jul 2022
- Primary completion date
- 1 Nov 2024
- Lead sponsor
- Mayo Clinic
- Diseases
- Migraine
- NCT number
- NCT05854992
What you commit to
- Study type: Observational
- Participants enrolled: 68419
- From 5 Jul 2022 to the primary completion date, 1 Nov 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Treatments of Migraine With Triptans in Individuals With Elevated Cardiovascular Risk:
- Inclusion:
- Aged \>=18 years
- At least 1 year history of migraine with or without aura
- Confirmed cardiovascular or cerebrovascular disease, including myocardial infarction (MI), coronary artery disease (CAD), cerebrovascular disease, stroke; or at least 2 cardiovascular risk factors, including diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, peripheral vascular disease;
- At least 1 year of prior triptan treatment or no previous triptan treatment.
- Exclusion:
- Prescription of ergot alkaloids or dihydroergotamine within 60 days before or after starting treatment
- Treatments of Migraine With Triptans in Pregnant Women
- Inclusion:
- Aged \>=18 years
- Pregnant woman
- Diagnosis of episodic or chronic migraine with or without aura before pregnancy
- Exclusion:
- Prescription of ergot alkaloids or dihydroergotamine \<= 60 days before pregnancy or during pregnancy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Florida Coordinator of this site? Confirm its status | Jacksonville | United States | Unknown status |
| Mayo Clinic - Arizona Coordinator of this site? Confirm its status | Phoenix | United States | Unknown status |
| Mayo Clinic Minnesota Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.